What Is Cytologic Atypia and Is It Cancer?

Cytologic atypia is not cancer. It is a pathologist’s way of saying that cells collected from a biopsy, swab, or body fluid look abnormal under the microscope but do not meet the full criteria for a cancer diagnosis. Think of it as a yellow traffic light: something has changed in the cells, the change deserves attention, but it does not mean you have a malignancy. What it does mean, and how urgently you need to act on it, depends heavily on where in the body those cells came from and what kind of abnormality the pathologist saw.

What Pathologists Actually See

When a pathologist examines a tissue sample, they are looking at individual cells and how those cells are organized. Normal cells have predictable shapes, sizes, and internal structures. Atypical cells deviate from that pattern in ways that catch a trained eye: the nucleus might be larger or darker than expected, the cell might be dividing more actively, or the architecture of the tissue might look disorganized. In one case report of a gingival tumor, for example, pathologists noted cells with conspicuous nucleoli, darkened nuclei, and increased division activity, and they interpreted those features as cytologic atypia that raised the possibility of a malignant process without confirming one.¹

The word “atypia” itself simply means “not typical.” It is intentionally vague, and that vagueness is both its strength and its frustration. It lets pathologists flag something concerning without overdiagnosing cancer. But it also leaves patients in an uncomfortable middle ground, unsure whether they should be worried or relieved.

Atypia in the Cervix

The most common place people encounter cytologic atypia is on a Pap smear result. The term you are most likely to see is ASCUS, which stands for atypical squamous cells of undetermined significance. It is, by design, the lowest-concern abnormal result a Pap smear can return. Most ASCUS findings are caused by inflammation, hormonal shifts, or a transient human papillomavirus (HPV) infection that the body clears on its own.

That said, a small but real fraction of ASCUS results are early signals of something more serious. A large Norwegian study following over 10,000 women with ASCUS Pap smears found that about 10% were diagnosed with high-grade precancerous changes within seven years, and roughly 0.6% developed invasive cervical cancer in that window.² Those numbers are low in absolute terms, but they were still 15 to 30 times higher than the risk in women whose Pap smear was completely normal. Even women whose follow-up Pap came back normal after an initial ASCUS result carried more than three and a half times the long-term risk of precancer or invasive cancer compared with the general screening population.

This is why HPV testing is now a standard next step after an ASCUS result. Research from South India tracking women with ASCUS over seven years found that persistence of high-risk HPV strains was the key factor driving progression to more serious lesions, and the study’s authors recommended routine HPV analysis for all women with ASCUS cytology.³ If you test positive for a high-risk HPV type, your doctor will typically recommend colposcopy, a closer look at the cervix. If HPV is negative, a repeat Pap in a year is usually enough.

Atypia in the Breast

In breast tissue, the most common atypia diagnosis is atypical ductal hyperplasia (ADH). This means the cells lining a milk duct are growing faster than normal and have some features that look like early abnormal changes, but they stop short of what a pathologist would call ductal carcinoma in situ (DCIS), the earliest form of non-invasive breast cancer.

ADH does raise your long-term breast cancer risk. A study drawing on a large and diverse cohort found that within ten years of an ADH diagnosis, the rate of invasive breast cancer was roughly two and a half times higher than in women without ADH, with about 5.7% of women with ADH developing invasive cancer over a decade, compared with 2.2% of women without it.⁴ A separate long-term study found that about 17% of patients with breast atypia experienced a subsequent breast event over extended follow-up, with roughly half of those events occurring in the first five years.⁵ That study also found that clinical features at the time of the atypia diagnosis did not reliably predict who would go on to develop cancer, reinforcing the idea that atypia signals a general, body-wide elevation in risk rather than a problem confined to one spot.

Management after a breast atypia finding has been debated for years. Some guidelines call for surgical excision of the atypical area, while others support vacuum-assisted excision as a less invasive alternative. An analysis from a large UK screening cohort found that vacuum-assisted excision appeared to be as safe as surgical excision and that routine three-yearly screening afterward may be sufficient, suggesting that annual mammography for five years after atypia might be overly cautious for many women.⁶ Other institutions have developed size-based guidelines, recommending excision for larger lesions and follow-up for smaller ones where microcalcifications have been completely removed.⁷

Atypia in the Thyroid

Thyroid atypia shows up when a fine-needle aspiration biopsy of a thyroid nodule produces cells that a pathologist cannot confidently call benign or malignant. The formal label is “atypia of undetermined significance” or “follicular lesion of undetermined significance” (AUS/FLUS), and it is one of the more anxiety-producing diagnoses in medicine because the malignancy rate is genuinely uncertain and varies widely across institutions.

One hospital-based study found that about 29% of AUS/FLUS cases turned out to be malignant after surgery.⁸ A separate study reported a malignancy rate of about 35% among patients who went to surgery, with ultrasound features suggestive of malignancy being the strongest independent predictor of a cancerous outcome.⁹ These rates are considerably higher than the 5 to 15% range originally anticipated when the classification system was designed, which has led to ongoing discussions about how aggressively to manage these nodules.

Options after an AUS/FLUS result include watchful observation with repeat ultrasound, a second fine-needle biopsy, molecular testing, or surgery. The choice depends on a combination of the ultrasound appearance of the nodule, the patient’s clinical history, and increasingly, the results of molecular tests.¹⁰

Atypia in the Urinary Tract

In urine cytology, the corresponding gray-zone diagnosis is “atypical urothelial cells” (AUC). When a cytologist sees urine cells that look off but cannot be definitively called malignant, AUC is the result. The stakes here tend to be higher than in many other organs. One study from a Finnish center found that among AUC cases with histological follow-up, about 63% turned out to be malignant, and about a third of those were high-grade urothelial carcinoma.¹¹ A separate study of patients without a known history of bladder cancer found a similar malignancy rate of 63% among those diagnosed with AUC.¹²

A third study added nuance: looking at cellular features, pathologists found that increased cellularity, papillary cell clusters, irregular nuclear membranes, and very dark nuclei were more common in urine samples from patients who turned out to have cancer, while certain other features like cytoplasmic vacuolization pointed toward a benign reactive process.¹³ The bottom line for urinary atypia is that it warrants prompt investigation, usually with cystoscopy, because the probability of an underlying malignancy is meaningfully high.

Why Pathologists Sometimes Disagree

One of the underappreciated realities of atypia is that pathologists looking at the same slide do not always agree on the diagnosis. This is not a sign of incompetence; it reflects the fact that atypia sits on a spectrum where the boundaries are genuinely blurry. A study of expert breast pathologists in the UK and Ireland asked them to classify columnar cell lesions of the breast and found only “fair” agreement, with a kappa statistic of 0.22 for overall interobserver agreement.¹⁴ The most contentious cases were those where nuclear or architectural changes fell outside the textbook definitions of specific categories. Consensus was hardest to achieve precisely where it mattered most: in cases that did not fit neatly into any box.

A separate study analyzing diagnostic variability in breast pathology found that the majority of disagreements about atypia came down to subtle differences in professional opinion about whether the features present met the threshold for a given diagnosis.¹⁵ This is worth knowing as a patient. If you have received an atypia diagnosis and feel uncertain, seeking a second pathology opinion is a reasonable and common step, especially when the result would change your treatment plan.

How Molecular Testing Is Changing the Picture

Nowhere has molecular testing had a bigger impact on atypia management than in the thyroid. For years, the only options after an indeterminate thyroid biopsy were to repeat the biopsy, watch and wait, or go straight to surgery. Now, commercially available molecular tests can analyze the cells from a biopsy for genetic mutations and gene expression patterns associated with cancer, helping to sort nodules into “more likely benign” or “more likely malignant” categories before any surgical decision is made.¹⁶

A review of available molecular and imaging diagnostics found that no single test achieves both near-perfect sensitivity and specificity, and that the most accurate approach is likely a stepwise combination: first a sensitive “rule-out” test to identify nodules that are almost certainly benign, then a specific “rule-in” test for those that remain suspicious.¹⁷ However, clinicians still need to weigh test results alongside ultrasound findings and patient factors. One study noted that a “positive” molecular test result should not automatically dictate aggressive surgery, particularly for nodules that look very low-risk on ultrasound.¹⁸

Environmental Triggers

Atypia is not always a precursor to cancer driven by internal genetic events. External exposures can push cells toward atypia too. In the lungs, smoking is an overwhelming driver. A study of 300 subjects found cytologic atypia in sputum samples of about 5% of participants overall, but 93% of those atypical findings were in smokers, and the odds of lung cytologic atypia associated with smoking were roughly 30 times higher than in non-smokers.¹⁹ In the nasal passages, occupational exposure to heavy metals like nickel and copper has been linked to epithelial dysplasia in nasal polyps.²⁰ In the bladder, inflammation caused by prior treatments or instrumentation can produce cellular changes that mimic the look of atypia, making accurate diagnosis especially tricky.²¹

The practical lesson here is that atypia does not appear in a vacuum. Your exposure history, your medical history, and any recent procedures can all affect how cells look under a microscope. A pathologist who knows that you recently had bladder surgery or that you smoke a pack a day can interpret your results more accurately than one working blind.

The Emotional Weight of an Atypia Diagnosis

If you have ever received an “abnormal” result and spent days or weeks spiraling through worst-case scenarios online, you are not alone. A qualitative study of women between abnormal cervical screening results and follow-up colposcopy found that most were confused by their results, had no idea what a colposcopy was before being referred, and experienced significant anxiety in the waiting period. Most searched online and found what they described as misinformation, worst-case scenarios, and generic content that did not resolve their confusion.²²

This “land of the unknown,” as the researchers called it, is a real and underappreciated cost of atypia diagnoses. The medical system is built around definitive categories: you have cancer, or you do not. Atypia defies that binary, and the communication tools available to patients and even to many clinicians are not always well suited to explaining a finding that means “something is different, but we are not sure what it means yet.” If you are in this position, pressing your doctor for a clear explanation of what the next step is and why, rather than trying to interpret the pathology report yourself, is usually the most productive approach.

Artificial Intelligence in Atypia Screening

The fact that atypia diagnosis depends on a human being’s subjective interpretation of visual patterns makes it a natural target for artificial intelligence. Several research groups are developing AI systems that analyze digitized slides and flag atypical cells, aiming to reduce both the workload on pathologists and the inconsistencies that come from human judgment. A system tested on cervical cytology slides, designed with a “cytologist-in-the-loop” approach where AI assists rather than replaces human review, achieved higher sensitivity and specificity than junior cytologists working alone and reduced overall workload by more than a third.²³

In thyroid cytology, a systematic review concluded that AI can be especially effective at removing sources of error like subjective assessment and variation in staining.²⁴ Broader efforts in digital pathology are developing deep learning models that classify malignant cells on cytology slides, with the explicit goal of improving diagnostic consistency and enabling scalable screening in settings where expert pathologists are scarce.²⁵ These tools are still largely in the research and validation phase, not yet standard practice in most pathology labs. But the direction is clear: AI will increasingly serve as a second set of eyes for the gray-zone diagnoses that make atypia so challenging, potentially reducing the interobserver disagreement that currently makes the experience so uneven for patients.